|
www.aurobindo.com |
|
|
Hyderabad,
18th February, 2004 |
|
|
|
SUBSCRIPTION TO PREFERENTIAL ISSUE OF EQUITY
SHARES
|
| |
|
Aurobindo Pharma Limited ("Aurobindo") has today
issued 2,370,000 equity shares to Merlion India
Fund I Limited (“Merlion India”) at Rs 375 per
share, aggregating to Rs.88.9 crores. Merlion
India will have a 4.45% shareholding in the
Company’s fully-diluted post-issue equity, after
exercise of Promoter Warrants allotted recently.
Mr.Karam Butalia, Managing Director at Merlion
India and Global Head for Private Equity at
Standard Chartered has also been appointed a
Director of Aurobindo. Citigroup acted as the
exclusive arranger for this placement by
Aurobindo. |
|
“The induction of a strong long-term partner
such as Merlion India demonstrates the Company’s
positioning in the investor community” said Mr.
P. V. Ramaprasad Reddy, Chairman of the Company. |
|
“Aurobindo represents a key pharmaceutical
sector investment for Merlion India. With its
strong chemistry skills and cost-advantage,
Aurobindo will soon be able to transform itself
into a global generics player” added Mr. Karam
Butalia, Managing Director at Merlion India. |
|
For information, please contact: |
Mr. B. Adi Reddy
Company Secretary
Aurobindo Pharma Limited
Tel - 040 –5572 5333 |
Mr. Karam Butalia
Managing Director, Merlion India
Tel: +65- 6530 3250 |
|
|
|
|
|
|
PRESS
ROOM 